The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.
Tumors usurp established metabolic steps used by normal tissues for glucose utilization and ATP production that rely heavily on mitochondria and employ a route that, although involving mitochondria, includes a much greater dependency on glycolysis. First described by Otto Warburg almost nine decades ago [1], this aberrant phenotype becomes more pronounced with increased tumor malignancy [2]. Thus, while maintaining their capacity for respiration, tumors "turn more parasitic" by enhancing their ability to scavenge glucose from their surroundings. With excess glucose at hand, tumors shunt their metabolic flux more toward glycolysis than do their normal cells of origin, a strategy that allows for their survival when oxygen is limiting while providing them a mechanism to poison their extra-cellular environment with acid, thus paving the way for invasion and metastasis. Significantly, tumors harness a crucial enzyme to regulate and support this destructive path--to entrap and channel glucose toward glycolysis. This enzyme is an isoform of hexokinase, referred to as hexokinase type II, and also in abbreviated form as HK-2 or HK II. Due to many-faceted molecular features at genetic, epigenetic, transcriptional, and enzymatic levels, including sub-cellular localization to mitochondria, HK-2 facilitates and promotes the high glycolytic tumor phenotype [3]. Thus, HK-2 represents a pivotal model gene or enzyme that tumors "select for" during tumorigenesis in order to facilitate their destructive path. In this review, we examine the roles played by mitochondrial bound HK-2 within the context of the highly choreographed metabolic roulette of malignant tumors. Recent studies that outline how the aberrant glycolytic flux can be subverted toward a more "normal" metabolic phenotype, and how the glycolytic flux affects the tumor microenvironment to facilitate tumor dissemination are also described, including how these very features can be harnessed in new metabolic targeting strategies to selectively debilitate tumors.
Mathupala
Saroj P
SP
Department of Neurological Surgery and Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Ko
Young H
YH
Pedersen
Peter L
PL
D000818:Animals; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis; D006593:Hexokinase / Q000235:genetics / Q000378:metabolism; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D019344:Lactic Acid; D008928:Mitochondria / Q000378:metabolism*; D008954:Models, Biological; D027501:Monocarboxylic Acid Transporters / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D017494:Proton Pumps / Q000378:metabolism; D012106:Research / Q000266:history
D027501:Monocarboxylic Acid Transporters; D017494:Proton Pumps; D019344:Lactic Acid; D006593:Hexokinase; D005947:Glucose
Prog Exp Tumor Res. 1978;22:190-274
149996
Biochim Biophys Acta. 2002 Sep 10;1555(1-3):14-20
12206885
Pflugers Arch. 2009 Sep;458(5):981-92
19437033
Cancer Res. 1996 Jun 1;56(11):2468-71
8653677
Curr Med Chem. 2009;16(13):1561-87
19442134
Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75
15465013
Eur J Biochem. 1975 Jun 16;55(1):315-21
1175605
Ann N Y Acad Sci. 1986;488:438-50
3555259
Adv Exp Med Biol. 1977 May 22-24;92:363-80
205103
Arch Biochem Biophys. 1996 May 1;329(1):17-23
8619630
J Bioenerg Biomembr. 2008 Jun;40(3):123-6
18780167
Eur J Cell Biol. 2008 Sep;87(8-9):591-9
18328592
Int J Cancer. 1995 Jul 17;62(2):216-22
7622299
Biol Res. 2002;35(1):9-26
12125211
Cell. 2008 Sep 5;134(5):703-7
18775299
Cancer Cell. 2007 Jan;11(1):37-51
17222789
Radiother Oncol. 2009 Sep;92(3):329-33
19604589
AJNR Am J Neuroradiol. 1983 May-Jun;4(3):826-9
6308993
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
18032601
Cancer Res. 1988 Feb 15;48(4):913-9
3338084
J Biol Chem. 2001 Nov 16;276(46):43407-12
11557773
Cancer Res. 2009 Mar 15;69(6):2260-8
19276390
Pflugers Arch. 2004 Feb;447(5):619-28
12739169
Eur J Biochem. 2002 Jul;269(13):3226-36
12084063
J Biol Chem. 1981 Aug 25;256(16):8699-704
7263678
J Biol Chem. 2003 Apr 25;278(17):15333-40
12566445
Oncogene. 2006 Aug 7;25(34):4777-86
16892090
Science. 2009 May 22;324(5930):1029-33
19460998
Neurosurgery. 2006 Dec;59(6):1313-23; discussion 1323-4
17277695
Anticancer Res. 2006 Sep-Oct;26(5A):3561-6
17094483
Rev Physiol Biochem Pharmacol. 1995;126:65-198
7886381
Br J Cancer. 2008 Oct 7;99(7):989-94
18766181
J Biol Chem. 1995 Jul 14;270(28):16918-25
7622509
J Cancer Res Clin Oncol. 2009 Jul;135(7):867-77
19415328
J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S
18523064
J Biol Chem. 1997 Sep 5;272(36):22776-80
9278438
J Bioenerg Biomembr. 2007 Jun;39(3):211-22
17879147
Arch Biochem Biophys. 1995 Jan 10;316(1):206-14
7840618
Ann Neurol. 1984;15 Suppl:S138-46
6331282
Curr Genomics. 2007 Apr;8(2):113-28
18660845
Oncogene. 2006 Aug 7;25(34):4787-97
16892091
Cancer Res. 2006 May 15;66(10):5216-23
16707446
Biochem J. 1994 Oct 1;303 ( Pt 1):269-74
7945251
Science. 1956 Aug 10;124(3215):269-70
13351639
Cell Metab. 2006 Mar;3(3):177-85
16517405
Proc Natl Acad Sci U S A. 1977 Sep;74(9):3735-9
198801
J Exp Biol. 2003 Jun;206(Pt 12):2049-57
12756287
Neurosurgery. 2004 Dec;55(6):1410-9; discussion 1419
15574223
Biochim Biophys Acta. 1994 Nov 22;1219(3):660-8
7948023
Curr Pharm Des. 2008;14(7):685-98
18336315
Semin Cancer Biol. 2009 Feb;19(1):17-24
19101634
Cancer Res. 2003 Jul 15;63(14):3847-54
12873971
Cancer Lett. 2001 Nov 8;173(1):83-91
11578813
Science. 1956 Feb 24;123(3191):309-14
13298683
J Bioenerg Biomembr. 2007 Feb;39(1):73-7
17354062
Cancer Cell. 2006 Jun;9(6):425-34
16766262